Other languages Brii Biosciences Limited

Equities

2137

KYG1645A1094

Market Closed - Hong Kong S.E. Other stock markets 01:38:20 26/04/2024 pm IST			5-day change	1st Jan Change
1.16 ^HKD	+6.42%		+11.54%	-49.12%

25/03	Transcript : Brii Biosciences Limited, 2023 Earnings Call, Mar 25, 2024
22/03	Brii Biosciences Limited Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Brii Biosciences Limited Reports Earnings Results for the Full Year Ended December 31, 2023	22/03
VBI Vaccines Sells Rights to Hepatitis B Vaccine to Brii Biosciences	14/02
Brii Biosciences to Buy Rights to Hepatitis B Vaccine from VBI	14/02
Brii Biosciences Appoints Dr. Brian Alvin Johns as Chief Scientific Officer	03/01
PBrii Biosciences Limited Presents New Data Highlighting Progress Towards Achieving HBV Functional Cure at AASLD's The Liver Meeting 2023	14/11
Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating Brii-179 (Vbi-2601) in Combination with Peg-Ifn for the Treatment of Chronic Hepatitis B	06/23/06
Brii Biosciences Limited Announces Data from Interim Analysis of A Randomized, Placebo-Controlled and Double-Blinded Phase 2 Study of Brii-179	06/23/06
Brii Biosciences Limited Reports Earnings Results for the Half Year Ended June 30, 2023	22/23/22
Shionogi Inc. completed the acquisition of Qpex Biopharma, Inc. from Brii Biosciences Limited and Others.	31/23/31
Brii Biosciences Limited Announces Executive Changes	06/23/06
VBI Vaccines and Brii Biosciences Expand Hepatitis B Partnership To Address Both Prevention and Treatment in License and Collaboration Agreements for up to $437 Million Plus Royalties	06/23/06
Vir Biotechnology, VBI Vaccines Release Data Supporting Brii Biosciences Medical Assets in Treating Hepatitis B	26/23/26
Brii Biosciences Limited Announces Dosing of First Subject in Phase 1 Clinical Trial Evaluating BRII-297	01/23/01
Brii Biosciences' Loss Narrows Down in 2022	24/23/24
Brii Biosciences Limited Reports Earnings Results for the Full Year Ended December 31, 2022	24/23/24
Six Hong Kong-listed firms say their deposits at SVB are immaterial	12/23/12
Brii Biosciences Limited Announces Interim Findings from A Phase 2 Study	15/23/15
Brii Biosciences Limited Provides Update on Strategic Clinical Development Progress	27/22/27
Brii Biosciences Announces New Data from Two Phase 1 Studies	19/22/19
Brii Biosciences Limited Announces Topline Results from a Phase 1 Study Evaluating its Long-Acting, Single-Injection Therapy, BRII-296, in the Development for the Treatment of Postpartum Depression	26/22/26

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Brii Biosciences Limited

Equities

2137

KYG1645A1094

Other languages

Filters